Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Rating of “Hold” by Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned an average recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $70.75.

A number of research firms have weighed in on PBH. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th.

Prestige Consumer Healthcare Price Performance

PBH stock traded up $0.44 during mid-day trading on Tuesday, reaching $48.92. 347,087 shares of the company’s stock were exchanged, compared to its average volume of 673,677. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare has a 12-month low of $42.62 and a 12-month high of $77.67. The stock’s 50 day moving average is $48.47 and its 200 day moving average is $57.82. The company has a market cap of $2.32 billion, a price-to-earnings ratio of 12.51, a price-to-earnings-growth ratio of 1.57 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period in the previous year, the company earned $1.32 earnings per share. The company’s quarterly revenue was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, research analysts expect that Prestige Consumer Healthcare will post 4.45 EPS for the current year.

Insider Activity at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UMB Bank n.a. lifted its stake in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $29,000. Barrow Hanley Mewhinney & Strauss LLC increased its holdings in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after purchasing an additional 235 shares during the last quarter. Finally, Torren Management LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter worth approximately $35,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).